BioSpace News Archive

OliX Pharmaceuticals, Inc., a leading developer of RNAi therapeutics, announced that June Hyun Park, Ph.D., Principal Scientist at OliX Pharmaceuticals, will present at the second annual RNAi-Based Therapeutics Summit, being held virtually June 15-17, 2021.

Eli Lilly and Company (NYSE: LLY) will participate in the Guggenheim Biopharma Strategy Series – Biopharma’s Next Decade: Views from the Top on Global Strategy and Innovation – on Friday, June 18, 2021. Daniel Skovronsky, M.D., Ph.D., Lilly’s Chief Scientific and Medical Officer and President of Lilly Research Laboratories

The rising number of patients suffering with diabetes and adoption of injection pens over traditional syringes and vials is expected to increase the demand for pen needles over the forecast period.

The report highlights trends prevailing in the market, and the factors driving and hindering the market growth.

Certain patients with an aggressive form of ovarian cancer have a better chance of a cure through surgical removal of their tumor before chemotherapy instead of the reverse, a new study shows.

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced data from the first co-administration study of a SARS-CoV-2 vaccine candidate [Novavax, NVX-CoV2373] and an approved influenza vaccine

Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced financial results for the quarter ended March 31, 2021,

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of preliminary Phase 1 data from the single-dose portion of the study at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Virtual Annual Meeting

Growing demand for measuring creatinine for diagnosing kidney diseases is driving the revenue growth of the market.

Rising prevalence of lung disorders, increasing investments in research and development for drug discovery are some key factors surging growth of lung in vitro models market.